Sponsor: Roche Pharmaceuticals
Sponsor Study ID: CO44657
Study Title: A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
CTO #: 104139
NCT Number: NCT06065748
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Breast
Study Objectives: To evaluate the efficacy of Giredestrant compared with fulvestrant (both combined with CDK4/6i) in the ESR1m subgroup and FAS.